Hypereosinophilic syndrome: Diagnosis and treatment

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 5, 2007, Pages 422-427

  Peroš Golubičić, Tatjana ^a   Smojver Ježek, Silvana ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University Hospital for Lung Diseases Jordanovac   (Croatia)

Author keywords

Eosinophilia; Hypereosinophilic syndrome; Imatinib mesylate; Tyrosine kinase inhibitors

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; DASATINIB; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN; MEPOLIZUMAB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; RETINOIC ACID; TROPONIN;

BLOOD CELL COUNT; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; ELECTROCARDIOGRAM; EOSINOPHIL; EOSINOPHILIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC DISORDER; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; KARYOTYPING; LOW DRUG DOSE; LUNG FUNCTION TEST; MOLECULAR GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; THORAX RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; HUMANS; HYPEREOSINOPHILIC SYNDROME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PULMONARY EOSINOPHILIA; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 34748880703     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3281eb8eb8     Document Type: Review

References (48)

1. Hardy WR, Anderson RE. The hypereosinophilic syndrome. Ann Intern Med 1968; 68:1220-1229.
2. Chusid MJ, Dale DC, West BC, Wolf SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1-27.
3. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology & genetics of tumours of haematopoietic and lymphoid tissues. IARSPress: Lyon 2001.
4. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006; 133:468-492. This is an excellent, comprehensive review of all eosinophilia categories.
5. Sandrsen CJ. Interleukin 5, eosinophils, and disease. Blood 1992; 79:3101-3109.
6. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin 5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112-1120.
7. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80:947-958.
8. Tefferi A, Elliot MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc 2006; 81:553-563. This is an enlightening article with detailed overview of all the atypical myeloproliferative disorders, among which the clonal eosinophilias are included.
9. Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Prac Res Clin Haematol 2006; 19:535-569. This is an excellent, didactic, authoritative and exhaustive review article about all different categories of eosinophilia.
10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-1214.
11. Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007; 26:11-20. This is a very instructive review article which summarizes the recent advances in understanding the role of tyrosine kinases in the development of various malignancies, and their role in the development of resistance to tyrosine kinase inhibitors.
12. Tanaka Y, Kurata M, Togami K. Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with history of combination chemotherapy. Int J Hematol 2006; 83:152-155. This is the first case report of CEL with positive FIP1L1-PDGFRA fusion gene, with previous history of combination chemotherapy, which raises the possibility of therapy induced genetic damage.
13. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-4666.
14. Vandenberger P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA(+) chronic eosinophilic leukemias. Leukemia 2004; 18:734-742.
15. Miyazawa K, Kakazu N, Ohyashiki K. Clinical features of hypereosinophilic syndrome: FIP1L1- PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. Int J Hematol 2007; 85:5-10. Summing the previously reported data and adding their experience, the authors explicitly classify FIP1L1-PDGFRA fusion gene-positive disease as a distinct clinical entity.
16. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in a routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30:965-970. This is an excellent article which sums all the information about the clinically relevant events, especially the results of the therapy in patients with FIP1L1-PDGFRA-positive eosinophilias.
17. Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: World Health Organization classification of tumours. pathology & genetics of tumours of haematopoietic and lymphoid tissues. IARSPress: Lyon 2001; 29-31.
18. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827-832. This is the example where the search for the new fusion gene involving PDGFRA was targeted to the selected group, and resulted in the discovery of the new fusion gene.
19. Walz C, Curtis C, Schnittger S, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006; 45:950-956.
20. Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABLnegative chronic myeloproliferative disorders. Br J Haematol 2003; 120: 251-256.
21. Yamada Y, Rothenberg ME, Lee AW, et al. The FIP1L1- PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/ chronic eosinophilic leukemia (CEL)-like disease. Blood 2006; 107:4071-4079. This is the article which reports on the necessity of cooperation of FIP1L1-PDGFRA genes and IL-5 to induce an HES/CEL-like disease, thus reflecting the intricacy of events leading to eosinophil-associated disorders.
22. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome; a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002; 107:101-107.
23. Bacher U, Reiter A, Haferlach T, et al. A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. Haematologica 2006; 91:817-820. This is a very useful article for clinical practitioners, which shows the complexity of methods to demonstrate the clonality. They report a retrospective study on 40 patients with HES, combining cytomorphology, cytogenetic analysis, interphase FISH, and RT-PCR, to determine the value of these methods for demonstrating clonality in such cases.
24. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007; 6:550-566.
25. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78-92.
26. Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. QJ Med 1983; 52:1-22.
27. Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med 2006; 27:158-170.
28. Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA- positive hypereosinophilic syndrome. Br J Haematol 2005; 132:286-292.
29. Shah R, Ananthasubramaniam K. Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography. Echocardiography 2006; 23:689-691. This is the article which thoroughly describes the echocardiographic potentiality in the diagnosis of cardiac involvement in idiopathic HES.
30. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2003; 103:473-478.
31. Gleevec. Side effects and safety information. http://www.gleevec.com/ info/ page/safety-info [Accessed 25 May 2007].
32. Kerkela R, Grazzeti L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908-916. This is an excellent article presenting the precise and exhaustive research of imatinib cardiotoxicity.
33. Strebhardt K, Ulrich A. Another look at imatinib mesylate. N Engl J Med 2006; 355:2481-2482. This is a very good, didactic article about the clinical implications of basic research.
34. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with idiopathic hypereosinophilic syndrome treated with imatinib is predictive of adverse outcome. Blood 2003; 102:3456-3457.
35. Jabbour E, Cortes J, O'brien S, et al. New targeted therapies for chronic myelogenous leukemia: opportinities to overcome imatinib resistance. Semin Hematol 2007; 44 (1 Suppl 1):25-31. This is an excellent review article that positions the actual therapy strategies in the imatinib resistance in patients with CML.
36. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1- PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003; 3:459-469.
37. Lierman Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108:1374-1376. This report confirms the efficacy of low doses of sorafenib in overcoming the imatinib resistance in FIP1L1-PDGFRalpha positive CEL. It is of note that sorafenib has recently been approved for the treatment of renal cell carcinoma.
38. Verstovsek S, Giles FJ, Quintas-Cardama A, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1- PDGFRalpha expressing cells. Leuk Res 2006; 30:1499-1505. This article reports the activity of a novel tyrosine kinase inhibitor AMN107, against FIP1L1-PDGFRalpha expressing cells.
39. Dasatinib as therapy for myeloproliferative disorders (MPD). http://www. clinical.trials.gov/ct/search/dasatinib [Accessed 25 May 2007].
40. Asuo N. All-trans retinoic acid in the treatment of acute promyelocytic leukemia. Intern Med 2007; 46:91-93.
41. Robert C, Delva L, Balitrand N, et al. Apoptosis induction by retinoids in eosinophilic leukemia: implications of retinoic acid receptor-alpha signaling in all-trans retinoic acid hypersensitivity. Cancer Res 2006; 66:6336-6344. This is the basic research article which points to a new line of drugs to treat HES.
42. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114:26-40.
43. Klion AD, Bochner BS, Gleich GJ, et al. Approach to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol 2006; 117:1292-1302. This is an authoritative article which summarizes the opinions of a group of experts on the recent advances in the treatment of HES.
44. Garrett JK, Jameson SC, Thomson B, et al. Antiinterleukin-5 (mepolizumab) therapy for hypereosinophilic syndrome. J Allergy Clin Immunol 2004; 113:115-119.
45. Sefcick A, Sowter S, DasGupta E, et al. Alemtuzumab therapy for refractory hypereosinophilic syndrome. Br J Haematol 2004; 124:558-559.
46. Kim YJ, Prussian C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004; 114:1449-1455.
47. von Gunten S, Vogel M, Schaub A, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007; 119:1005-1011. This is an article that reports about the cytotoxic effects of IVIg preparations on eosinophilis of HES patients, with the projections of its therapeutic efficiency in vivo.
48. Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with the eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006; 38:319-320.